牛颈动脉生物移植物在血液透析通路中优于膨体聚四氟乙烯
单中心回顾性研究纳入2011-2014年98例患者的120条动静脉移植物,比较牛颈动脉(BCA)生物移植物与膨体聚四氟乙烯(ePTFE)的通畅率与并发症。
要点
- BCA与ePTFE一期和一期辅助通畅率无显著差异。
核心结论
- BCA与ePTFE的一期和一期辅助通畅率相似,但BCA二期通畅率更高,表明生物移植物耐久性更好。
研究设计与样本
- 单中心回顾性研究,纳入2011年1月1日至2014年6月30日期间98例患者的120条连续动静脉移植物。
临床怎么用
- 对于解剖条件不适合建立动静脉瘘的患者,BCA生物移植物可作为ePTFE的替代选择,因其二期通畅率更优。
局限性
- 单中心回顾性设计,样本量有限(120条移植物),可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Arteriovenous grafts remain reliable substitutes for permanent hemodialysis access in patients without a suitable autogenous conduit. Advances in conduit design and endovascular management of access-related complications question the preference for synthetic conduits over biologic grafts in contemporary practice. In this study, we compared outcomes between a bovine carotid artery (BCA) biologic graft and expanded polytetrafluoroethylene (ePTFE) grafts for hemodialysis access in a recent cohort of patients. METHODS: This was a single-institution retrospective review of 120 consecutive grafts placed in 98 patients between January 1, 2011, and June 30, 2014. Univariate methods (χ2, analysis of variance, t-test) were used to compare demographic and medical characteristics of patients who received each graft type. Kaplan-Meier, log-rank tests, univariate and multivariate logistic analyses, and Cox regression analyses were used to evaluate patency and graft complications. Outcomes were defined and analyzed according to reporting guidelines published by the Society for Vascular Surgery. RESULTS: Of the 120 grafts studied, 52 (43%) were BCA and 68 (57%) were ePTFE. Successful graft use for dialysis was 96% (95% confidence interval [CI], 90%-100%) for BCA and 84% (95% CI, 74%-93%) for ePTFE (P = .055). Comparing BCA vs ePTFE, estimates for primary patency were 30% vs 43% at 1 year and 16% vs 29% at 2 years (P = .27). Primary assisted patency was 36% vs 45% at 1 year and 24% vs 35% at 2 years (P = .57). Secondary patency was 67% vs 48% at 1 year and 67% vs 38% at 2 years (P = .05). There were no differences in primary (hazard ratio [HR], 0.70; 95% CI, 0.40-1.28; P = .25) and primary assisted (HR, 0.87; 95% CI, 0.46-1.65; P = .67) patency for BCA compared with ePTFE. However, secondary patency was higher for BCA compared with ePTFE (HR, 2.92; 95% CI, 1.29-6.61; P = .01). Graft infection rates during the study period were 15.4% for BCA and 20.6% for ePTFE (P = .47). The significant predictors of graft failure were higher body mass index (HR, 1.06; 95% CI, 1.00-1.11; P = .04) and hyperlipidemia (HR, 2.94; 95% CI, 1.27-6.76; P = .01). CONCLUSIONS: In this study of a recent cohort of patients who received arteriovenous grafts, primary and primary assisted patencies were similar between BCA and ePTFE grafts. However, secondary patency was higher for BCA, indicating better durability for the biologic graft than for ePTFE grafts in patients whose anatomy preclude placement of an arteriovenous fistula.
引用
- Arhuidese I, Reifsnyder T, Islam T, et al. Bovine carotid artery biologic graft outperforms expanded polytetrafluoroethylene for hemodialysis access. J Vasc Surg. 2017. PMID: 28236920. doi:10.1016/j.jvs.2016.10.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。